⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KOD News
Kodiak Sciences Inc Common Stock
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
prnewswire.com
KOD
4 Explosive Stories Enter the Investor Spotlight
globenewswire.com
KOD
MEDS
NTHI
KNRX
Form 8-K
sec.gov
KOD
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing
prnewswire.com
KOD
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
prnewswire.com
KOD
Ferromagnetic Detection Systems Market to Reach $1.92 Billion by 2030 as MRI Safety and Security Investments Accelerate
globenewswire.com
ETS
CMA
KOD
Form 8-K
sec.gov
KOD
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
prnewswire.com
KOD
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
prnewswire.com
KOD
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
prnewswire.com
KOD